JUNO Juno Therapeutics Inc.

60.75
+1.69  (3%)
Previous Close 59.06
Open 59.34
Price To book 6.04
Market Cap 6935649557
Shares 114,172,897
Volume 616,222
Short Ratio 5.64
Av. Daily Volume 2,359,178

SEC filingsSee all SEC filings

  1. 8-K - Current report 171191435
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171185211
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171169517
  4. 8-K - Current report 171168982
  5. 8-K - Current report 171147740

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b initiated.
JCAR017 in combination with durvalumab - PLATFORM
Non-hodgkin Lymphoma
Phase 1 updated data to be presented at ASH December 11, 2017.
JCAR017
r/r B cell non-Hodgkin lymphoma - cancer
Phase 1/2 ongoing
JCAR014
Adults with advanced B cell malignancies
Phase 2 clinical hold announced July 7, 2016. Clinical hold lifted July 12, 2016. Clinical hold placed back on - November 23, 2016. Announced March 1, 2017 that it will not continue development.
JCAR015
Relapsed/ refractory B cell acute lymphoblastic leukemia

Latest News

  1. ETFs with exposure to Juno Therapeutics, Inc. : November 17, 2017
  2. Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms
  3. Harry Boxer on four stocks rallying today
  4. Today’s Research Reports on Stocks to Watch: Juno Therapeutics and Insmed Incorporated
  5. Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According to a Recently Filed Shareholder Derivative Lawsuit
  6. 3 Top Biotech Stocks for 2018
  7. 3 High-Growth Stocks That Are Just Getting Started
  8. Featured Company News - US FDA Clears Sarepta Therapeutics' IND Application for GALGT2 Gene Therapy Program; Nationwide Children's Hospital Prepared to Initiate Phase-1/2a Clinical Trials for Patients with DMD
  9. Edited Transcript of JUNO earnings conference call or presentation 1-Nov-17 8:30pm GMT
  10. Juno Therapeutics to Present at November 2017 Investor Conferences
  11. Bluebird: Can It Keep Singing?
  12. 3 Biotech Stocks That Soared This Week: Are They Buys?
  13. Juno Therapeutics, Inc. :JUNO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
  14. 4 Biggest Technical Levels To Watch Friday Morning
  15. 3 Reasons It's Smart to Buy Celgene's Stock Now
  16. Why Juno Therapeutics Shares Are Going Up 21.2% Today
  17. Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug
  18. Redfin, Weyerhaeuser and others vie for coolest office award (Photos)
  19. Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis

SEC Filings

  1. 8-K - Current report 171191435
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171185211
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171169517
  4. 8-K - Current report 171168982
  5. 8-K - Current report 171147740
  6. D - Notice of Exempt Offering of Securities 171125166
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171102169
  8. 8-K - Current report 171097886
  9. 424B4 - Prospectus [Rule 424(b)(4)] 171097850
  10. S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] 171096688